title: Effect of acute and repeated treatment with desipramine or methylphenidate on serial reversal learning in rats.
abstract: Administration of stimulant and non-stimulant drugs that inhibit monoamine reuptake is known to improve cognitive and behavioral symptoms of attention deficit hyperactivity disorder (ADHD). Although this may reflect acute actions of these drugs, clinical observations suggest that prolonged treatment with these agents may result in a better therapeutic outcome. In the current study, we compared the effects of acute and repeated treatment with the stimulant drug, methylphenidate (MPH), and the non-stimulant norepinephrine reuptake inhibitor desipramine (DMI) in rats performing a reversal learning task meant to study behavioral flexibility in rats. Furthermore, we tested the effect of an acute challenge administration with these agents or vehicle on reversal performance of rats repeatedly treated with the drug or vehicle. Our results suggest the acute and repeated treatment with DMI improves reversal learning performance in a qualitatively and quantitatively similar manner. Further repeated treatment with DMI seems to produce a reversal learning improvement that persists at least 24 h after drug administration. Repeated MPH treatment only improved performance in the first within session reversal administered, suggesting that its beneficial effects may depend upon the complexity of the reversal condition tested. The differential outcome produced by stimulant and non-stimulant medications in this study may be explained in light of their distinct actions on brain catecholaminergic systems.
authors.affiliation: Department of Psychology, University of California Los Angeles, PO Box 951563, Los Angeles, CA 90095-1563, USA.
authors.forename: Emanuele
authors.initials: E
authors.lastname: Seu
authors.forename: J David
authors.initials: JD
authors.lastname: Jentsch
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology*; D003891:Desipramine / Q000494:pharmacology*; D004193:Discrimination Learning / Q000187:drug effects; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D020318:Rats, Long-Evans; D011930:Reaction Time; D012193:Reversal Learning / Q000187:drug effects*; D012691:Serial Learning / Q000187:drug effects*; D013997:Time Factors
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D003891:Desipramine
references.citation: Psychopharmacology (Berl). 2004 Sep;175(3):319-30
references.pmid: 15138760
references.citation: J Neurosci. 2002 Jan 15;22(2):389-95
references.pmid: 11784783
references.citation: Neuropsychopharmacology. 2002 Nov;27(5):699-711
references.pmid: 12431845
references.citation: J Abnorm Child Psychol. 1995 Aug;23(4):411-37
references.pmid: 7560554
references.citation: J Am Acad Child Adolesc Psychiatry. 1995 Jul;34(7):886-96
references.pmid: 7649959
references.citation: J Child Adolesc Psychopharmacol. 2001 Fall;11(3):251-65
references.pmid: 11642475
references.citation: Neurosci Lett. 2002 Aug 16;328(3):319-21
references.pmid: 12147334
references.citation: Psychopharmacology (Berl). 2009 Jan;202(1-3):505-19
references.pmid: 18604598
references.citation: J Neurosci Methods. 2007 Jun 15;163(1):83-91
references.pmid: 17400296
references.citation: Biol Psychiatry. 2005 Mar 1;57(5):456-63
references.pmid: 15737659
references.citation: Arch Gen Psychiatry. 2002 Jul;59(7):649-56
references.pmid: 12090818
references.citation: J Psychopharmacol. 2003 Sep;17(3):332-6
references.pmid: 14513926
references.citation: Cereb Cortex. 2007 Jun;17(6):1364-75
references.pmid: 16920883
references.citation: Psychopharmacology (Berl). 2009 Jan;202(1-3):497-504
references.pmid: 18535818
references.citation: Neuropharmacology. 2006 May;50(6):755-60
references.pmid: 16427661
references.citation: Biol Psychiatry. 2007 Jun 15;61(12):1361-9
references.pmid: 16950217
references.citation: Biol Psychiatry. 2006 Nov 15;60(10):1111-20
references.pmid: 16806100
references.citation: Pharmacol Biochem Behav. 2007 Oct;87(4):426-33
references.pmid: 17599397
references.citation: Behav Brain Funct. 2005 Oct 03;1:16
references.pmid: 16202140
references.citation: Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93
references.pmid: 10414438
references.citation: Science. 2006 Feb 10;311(5762):861-3
references.pmid: 16469930
references.citation: J Child Psychol Psychiatry. 2006 Nov;47(11):1184-94
references.pmid: 17076758
references.citation: Neuropsychopharmacology. 2008 Apr;33(5):1028-37
references.pmid: 17637611
references.citation: Neuropsychopharmacology. 2006 Nov;31(11):2376-83
references.pmid: 16855530
references.citation: Neuropsychopharmacology. 2008 Dec;33(13):3190-200
references.pmid: 18418364
references.citation: J Neurosci. 2009 Apr 15;29(15):4690-6
references.pmid: 19369539
references.citation: J Clin Psychopharmacol. 2004 Feb;24(1):30-5
references.pmid: 14709944
references.citation: J Neurochem. 2006 Jan;96(2):473-81
references.pmid: 16336224
references.citation: Biol Psychiatry. 2003 Dec 15;54(12):1465-8
references.pmid: 14675812
references.citation: J Child Adolesc Psychopharmacol. 2001 Spring;11(1):25-34
references.pmid: 11322742
references.citation: J Neurosci. 2000 Mar 15;20(6):RC65
references.pmid: 10704519
references.citation: Am J Psychiatry. 1998 May;155(5):693-5
references.pmid: 9585725
references.citation: Nature. 1996 Mar 7;380(6569):69-72
references.pmid: 8598908
references.citation: J Abnorm Child Psychol. 2003 Feb;31(1):105-20
references.pmid: 12597703
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):34-41
references.pmid: 17714843
references.citation: Neuroreport. 2002 Dec 20;13(18):2453-7
references.pmid: 12499848
references.citation: J Neurochem. 1997 May;68(5):2032-7
references.pmid: 9109529
references.citation: Brain Res. 2002 May 17;936(1-2):58-67
references.pmid: 11988230
references.citation: J Abnorm Child Psychol. 2000 Jun;28(3):227-35
references.pmid: 10885681
references.citation: J Child Adolesc Psychopharmacol. 2005 Aug;15(4):664-70
references.pmid: 16190797
references.citation: Neuropsychopharmacology. 2007 May;32(5):1000-10
references.pmid: 17077810
references.citation: Neuropsychopharmacology. 2007 Jul;32(7):1583-99
references.pmid: 17164816
references.citation: J Neurochem. 2004 Nov;91(3):683-93
references.pmid: 15485498
references.citation: Psychopharmacology (Berl). 2007 Jun;192(2):193-206
references.pmid: 17277934
references.citation: J Abnorm Child Psychol. 1995 Apr;23(2):235-66
references.pmid: 7642836
references.citation: Behav Brain Res. 2007 May 16;179(2):219-28
references.pmid: 17337305
references.citation: J Child Psychol Psychiatry. 2004 Feb;45(2):293-305
references.pmid: 14982243
references.citation: J Psychopharmacol. 2000;14(3):299-302
references.pmid: 11106312
references.citation: Psychol Med. 1999 May;29(3):527-38
references.pmid: 10405075
references.citation: J Neurosci. 2003 Feb 1;23(3):1066-71
references.pmid: 12574437
references.citation: J Abnorm Child Psychol. 1989 Oct;17(5):473-91
references.pmid: 2681316
references.citation: Biol Psychiatry. 2007 Nov 1;62(9):977-84
references.pmid: 17644072